PROTEÍNA QUIMÉRICA, COMPOSIÇÕES VACINAIS, KIT DIAGNÓSTICO E USOS
A chimeric protein combining epitopes from Gp63, A2, HSP70, and LiP2a proteins addresses the lack of effective vaccines and diagnostics for Leishmania spp., inducing a strong immune response and enabling comprehensive disease prevention and detection.
Patent Information
- Application Number
- BR102025008541
- Authority / Receiving Office
- BR · BR
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2025-04-30
- Publication Date
- 2026-11-10
AI Technical Summary
Current treatments for visceral leishmaniasis lack a single effective vaccine and rely on expensive and toxic chemotherapeutics, while existing vaccines and diagnostic kits are not comprehensive in addressing various Leishmania species, and there is a need for improved control measures to prevent the spread of the disease.
A chimeric protein composed of immunogenic epitopes from Gp63, A2, HSP70, and LiP2a proteins of Leishmania spp., expressed in prokaryotic or eukaryotic systems, is developed, purified, and used in vaccine compositions and diagnostic kits to induce a broad immune response against different Leishmania species.
The chimeric protein effectively induces a robust immune response, including antibody production and cytokine activation, providing protection against Leishmania spp. infections and facilitating accurate diagnosis.
Description
24 Chimeric protein, vaccine compositions, diagnostic kit and uses Field of invention
[001] The present invention presents a novel chimeric protein, which has in its sequence immunogenic epitopes of the Gp63, A2, HSP70 and LiP2a proteins of Leishmania spp, linked together by linkers. In the present invention, the chimeric protein has immunogenic capacity, being able to induce an anti-Leishmania immune response in a model organism. Thus, the present invention also presents vaccine compositions containing said protein, a diagnostic kit comprising the chimeric protein, and uses related to the protein, vaccine compositions, revealed kit and associated nucleotide sequence. The present invention integrates the broad area of biotechnology, presenting potential application in both human and animal health. Fundamentals of the invention
[002] Visceral leishmaniasis (VL), caused by parasites of the Leishmania complex, is endemic in about 80 countries, located mainly in African regions, parts of Asia and the Americas (Pan American Health Organization, PAHO. Guidelines for the treatment of leishmaniasis in the Region of the Americas. 2022) and can lead to death in approximately 90% of cases. In Brazil, 1684 cases were registered in 2022, with the highest incidence among people over 50 years of age, mainly men (Health Surveillance Secretariat, Department of Epidemiological Surveillance - Ministry of Health, SVSA / MS. Manual of visceral leishmaniasis - clinical recommendations for reducing lethality, 2022). To date, there is no single candidate vaccine to prevent human leishmaniasis infection; therefore, disease prevention is mainly based on controlling the transmitting sandfly through cleaning the area and using insecticides. Petition 870250034541, dated 04 / 30 / 2025, pp. 12 / 43 / 24 (Health Surveillance Secretariat, Epidemiological Surveillance Department, Ministry of Health, SVSA / MS, 2024). Furthermore, currently available treatments do not completely eliminate the parasite and rely solely on expensive and / or toxic chemotherapeutic options. Therefore, there is an urgent need to develop other control measures against VL to halt its spread, such as the development of vaccines, reducing the incidence of the disease in animals and individuals, and decreasing transmission.
[003] Another way to combat visceral leishmaniasis is through the control of animals, mainly dogs and cats, infected with the parasite, since they act as parasitic reservoirs. In this sense, different approaches can be found in the literature in search of the development of efficient vaccines and accurate diagnostic kits for the prevention and detection of Leishmania spp in mammals, mainly in domestic animals such as dogs and cats.
[004] Different proteins are considered candidates for the development of prophylactic techniques, whether as drug targets or targets for optimization and modifications for the development of vaccine compositions. One of the main target proteins for vaccine development is Gp63. Gp63 is expressed on the surface of parasites and is used in the process of cell infection, as well as in parasite evasion. The use of Gp63 has already been shown to be capable of inducing a T cell response (Russo et al., 1993. PMID: 8482855), inducing immunogenicity and protection (Walker et al., 1998 DOI: 10.1089 / hum.1998.9.13-1899; Sachdeva et al., 2009 DOI: 10.1371 / journal.pone.0007880). Furthermore, Shams and colleagues (2021, DOI:10.1007 / s11756-021-00934-3) observed through bioinformatics characteristics of the Gp63 protein of L. major that position it as a promising vaccine candidate. Petition 870250034541, dated 04 / 30 / 2025, page 13 / 43 / 24
[005] A2 proteins are predominantly expressed in the amastigote stage of Leishmania, first described in Leishmania (Leishmania) donovani. A2 has been identified as an important virulence factor of the parasite. Studies show the ability of the A2 protein to induce lymphocyte activation and be related to protection (Garin et al, 2005. DOI:10.1186 / 1471-2334-5-18; Martins et al., 2006. DOI:10.1128 / IAI.02032-05; Porozzi et al., 2007 DOI:10.1128 / CVI.00420-06).
[006] The 70 kDa heat shock protein (HSP70) is a chaperone molecule that helps the Leishmania parasite return to homeostasis after being subjected to different types of stress during its life cycle, and has been described as an immunodominant B cell epitope (Wallace et al., 1992, DOI:10.1128 / iai.60.7.2688-2693.1992; Quijada et al., 1998, DOI:10.1016 / s0165- 2478(98)00071-6).
[007] Leishmania ribosomal acidic protein P2 (LiP2a) is a protein that is part of the 60S subunit of ribosomes. It plays a fundamental role in the elongation step of protein synthesis. LiP2a has been described as a relevant antigen during human and canine visceral leishmaniasis, and possesses immunostimulatory properties (Soto et al., 2000; DOI:10.1046 / j.1365-2249.2000.01372.x; Soto et al. 1995; DOI:10.1111 / j.1365-2249.1995.tb03661.x).
[008] In the present invention, a chimeric protein with sufficient immunogenic capacity for inducing an immune response in mammals has been developed. This protein contains immunogenic epitopes from different Leishmania species, enabling increased coverage of vaccine compositions containing it. It should be noted that the use of heterologous proteins for the development of vaccine compositions against leishmaniasis is already reported in the state of the art. However, the present invention discloses a chimeric protein (QL) that has 17 immunogenic epitopes screened by computational techniques. Of these 17 epitopes, 13 originate from the Gp63 protein; 01 Petition 870250034541, dated 04 / 30 / 2025, page 14 / 43 / 24 epitope originating from protein A2, 01 epitope originating from protein HSP70 and 01 epitope originating from protein LiP2a. The revealed chimeric protein can be expressed by prokaryotic and eukaryotic organisms. After its expression, the protein is purified and used in vaccine compositions and molecular diagnostic kits.
[009] The use of epitopes from the four proteins in a chimera presents several advantages over recombinant proteins alone. Linear peptides, for example, when joined in the chimera, preserve their ability to recognize parasites. This is because conformational epitopes can exhibit modifications in their structural integrity, impairing their immunoreactivity in the recombinant protein. The structure of epitopes truncated from linkers facilitates epitope presentation, as they are smaller than the proteins tested in other studies that evaluated the Gp63, A2, LiP2a, and HSP70 proteins alone. Furthermore, the literature reports the role of some proteins used in this invention for epitope mapping. Regarding the Gp63 protein, for example, some authors present evidence of the role of Gp63 in susceptibility to infection. On the other hand, evidence points to the protective effects of the protein used alone (Yoon et al., 2024; DOI: 10.1371 / journal.pntd.0012229).
[0010] Regarding the parasite Leishmania spp., it is known that its protein expression profile varies according to its life cycle. Thus, the immunogenic epitopes used in this invention exhibit a high degree of conservation among different Leishmania species, being observed in parasites that cause both visceral and cutaneous leishmaniasis. In summary, the present invention aims to induce a more effective immune response against more promising and comprehensive epitopes due to the use of sequences from different species and forms of the parasite through the production of long-lived memory T cells, capable of Petition 870250034541, dated 04 / 30 / 2025, page 15 / 43 / 24 respond promptly to infection, inducing the production of effector cytokines, cell activation and, consequently, a protective response.
[0011] Patent document WO2013110824, entitled “Multi-component chimera for use as a vaccine against infection by Leishmania spp. in mammals,” discloses an immunogenic composition that confers protection against canine and visceral leishmaniasis in mammals. To this end, this invention presents a recombinant DNA molecule comprising a fusion of different genes encoded in the pathogen of interest. These genes encode six pathoantigens involved in parasitic virulence; namely, the genes encoding histones H2A, H2B, H3, and H4, the antigenic protein A2, and the heat shock protein HSP70. The gene sequence is inserted into a prokaryotic or eukaryotic expression plasmid to deliver the gene sequence of interest. Thus, the invention reported in WO2013110824 concerns the development of a novel DNA vaccine against leishmaniasis. In this way, the expression of the chimeric protein is induced in the organism of the immunized individual.On the other hand, the present invention utilizes a chimeric protein formed by immunogenic fragments detected in the Gp63, A2, HSP70, and LiP2a proteins. In the present invention, immunization is performed with vaccine compositions containing the QL protein, expressed in prokaryotic or eukaryotic systems, previously purified and quantified.
[0012] Document WO1996010081, entitled “VACCINE COMPOSITION COMPRISING RECOMBINANT BCG EXPRESSING GP63 FUSION PROTEIN,” presents an immunogenic composition comprising the beta-lactamase fusion protein or its fragment, and the Gp63 protease from L. major. These recombinant proteins are cloned into an expression vector and then inserted into an optimized strain of Bacillus Calmette-Guérin (BCG), which in turn will integrate the vaccine composition. Thus, immunization is achieved through the administration of the recombinant strain. Therefore, although patent document WO1996010081 uses the GP63 protein, significant differences are noted. Petition 870250034541, dated 04 / 30 / 2025, page 16 / 43 6 / 24 between the technology existing in the state of the art and the present invention. This is because in the present technology, fragments present in GP63 were used, and not the protein in its entirety. Furthermore, the present invention has epitopes obtained from other proteins, allowing the use of the QL protein in prophylaxis for all types of leishmaniasis, in addition to recognizing different evolutionary forms of the parasite. Furthermore, QL is purified, treated to remove LPS, and only then administered in immunization; thus, it is a recombinant heterologous vaccine.
[0013] Patent documents WO2006122382 and WO2009089605 utilize recombinant proteins Fucose-mannose ligand and A2, all derived from Leishmania infantum. These technologies utilize molecules obtained from Leishmania infantum, differing substantially from the present invention, which discloses a chimeric protein containing, in its sequence, epitopes of different Leishmania spp. proteins. On the other hand, document ES2260440 employs secreted molecules from Leishmania spp., in promastigote and / or amastigote forms; and differs from the present invention in that these are proteins that compose the parasite's structure and are not secreted.
[0014] Therefore, the present invention presents a chimeric protein (QL), defined by SEQ ID NO: 01, capable of inducing an immune response against Leishmania spp., in preferential modalities, against different species of the Leishmania parasite, which causes leishmaniasis, such as Leishmania infantum, which causes visceral leishmaniasis (VL), and Leishmania braziliensis, L. major, L. amazonensis, which cause cutaneous / mucocutaneous leishmaniasis. The present invention also relates to immunogenic compositions containing the protein defined by SEQ ID NO: 01 as an immunogen. The present invention also relates to an immunodiagnostic kit that uses the chimeric protein defined in SEQ ID NO: 01 as an antigen for the detection of anti-Leishmania antibodies in the target sample. Furthermore, the present invention reveals uses of QL for the development of prophylactic treatments against leishmaniasis, such as vaccination and testing. Finally, the present invention also relates to the use of Petition 870250034541, dated 04 / 30 / 2025, page 17 / 43 / 24 nucleotide sequence defined in SEQ ID NO: 02, for obtaining the chimeric protein QL. Brief description of the drawings
[0015] The present invention can be understood from the listed figures. Figure 1 presents a graphical representation of the dosage of LPS levels present in the QL before and after LPS removal. - Figure 2 presents the graphical representation of IgG antibody production after immunization with PBS (n=4) or QL (n=4), using a single dose of the protein. In (A), the evaluation of recognition of the chimeric protein is shown. In (B), the evaluation of recognition of the soluble parasite antigen is shown. Figure 3 presents a graphical representation of IgG antibody levels after three doses of QL administered to mice (n=4) for recovery of anti-QL antibodies. Each bar in the graph represents an administration dose, i.e.: 1st dose; 2nd dose and 3rd dose. Figure 4 presents a graphical representation of the results obtained from an ELISA immunoassay using three different concentrations of QL as a sensitizer: 0.1 pg / mL, 0.5 pg / mL, and 1 pg / mL. The evaluation was performed using serum from dogs (C) and humans (D) infected (positive - red) and uninfected (negative - blue) for Leishmania infantum (visceral leishmaniasis). Figure 5 presents a graphical representation of the Luminex assays of the supernatant from splenocyte cultures stimulated with soluble parasite proteins. The graphical representation shows the Luminex results for pro-inflammatory cytokines (E): IL-1β (E1); IL-2 (E2); IL-6 (E3); IL-23 (E4); IFN-γ (E5); IL-12p70 (E6); GM-CSF (E7) and TNF-α (E8). The X-axis of the graph shows the Luminex results for animals after 4 weeks of immunization. Petition 870250034541, dated 04 / 30 / 2025, page 18 / 43 / 24 (wpi), and 4 weeks (4wpc), 8 weeks (8wpc) and 12 weeks (12wpc) after challenge with the wild strain. In the graph, the blank (unfilled) columns show the results obtained from animals immunized with the negative control PBS, while the blue (filled) columns show the results obtained after immunization of the animals with 25 pg of QL in three doses. The asterisks (* and **) throughout the graph signify a statistically significant difference (p<0.05 and p<0.01, respectively). Figure 6 presents a graphical representation of the Luminex assays of the supernatant from splenocyte cultures stimulated with soluble parasite proteins. The graphical representation shows the Luminex results for anti-inflammatory cytokines (F): IL-10 (F1); IL-5 (F2); IL-9 (F3); IL-13 (F4); IL-27 (F5). The X-axis of the graph shows the Luminex results for animals after 4 weeks of immunization (wpi), and 4 weeks (4wpc), 8 weeks (8wpc), and 12 weeks (12wpc) after challenge with the wild-type strain. In the graph, the blank (unfilled) columns show the results obtained from animals immunized with the negative control PBS, while the blue (filled) columns show the results obtained after immunization of the animals with 25 pg of QL in three doses. The asterisks (*, **, ***) throughout the graph indicate a statistically significant difference (p<0.05, p<0.01 and p<0.001, respectively). Figure 7 presents a graphical representation of the Luminex assays of the supernatant from splenocyte cultures stimulated with soluble parasite proteins (E). The graphical representation shows the Luminex results for TH17 cytokines (G): IL-22 (G1); IL-17A (G2). The X-axis of the graph shows the Luminex results for animals after 4 weeks of immunization (wpi), and 4 weeks (4wpc), 8 weeks (8wpc), and 12 weeks (12wpc) after challenge with the wild-type strain. In the graph, the blank (unfilled) columns show the results obtained from animals immunized with the negative control PBS, while the blue (filled) columns show the results... Petition 870250034541, dated 04 / 30 / 2025, page 19 / 43 / 24 obtained after immunization of animals with 25 pg of QL; in three doses. The asterisks (*, **) throughout the graph signify a statistically significant difference (p<0.05 and p<0.01, respectively). Figure 8 presents a graphical representation of the ELISA assays for obtaining the quantity of specific antibodies produced. The X-axis of the graph shows the absorbance (OD) results of IgG antibodies (H), being: total IgG (H1), IgG1 (H2) and IgG2 (H3); from samples collected after 4 weeks of immunization (wpi), and 4 weeks (4wpc), 8 weeks (8wpc) and 12 weeks (12wpc) after challenge with the wild strain. In the graph, the blank (unfilled) circles show the results obtained from animals immunized with the negative control PBS, while the blue (filled) circles show the results obtained after immunization of the animals with 25 pg of QL; in three doses. The asterisk (*) along the graph indicates a statistically significant difference (p<0.05). Figure 9 presents a graphical representation of the serial dilution assays of parasite load (I) in animals immunized and challenged with a wild-type strain, evaluating the spleen (I1) and liver (I2). The X-axis of the graph shows the results of the number of parasites recovered after 4 weeks (4wpc), 8 weeks (8wpc), and 12 weeks (12wpc) after challenge with the wild-type strain. In the graph, the blank (unfilled) columns show the results obtained from animals immunized with the negative control PBS, while the blue (filled) columns show the results obtained after immunization of the animals with 25 pg of QL in three doses. The letter (a) throughout the graph signifies a statistically significant difference compared to the control group at the same evaluation time. Description of the invention
[0016] The present invention relates to the chimeric protein defined by SEQ ID NO: 01, which can be expressed in heterologous prokaryotic or eukaryotic systems. A Petition 870250034541, dated 04 / 30 / 2025, p. 20 / 43 / 24 SEQ ID NO: 01 comprises 16 immunogenic peptides (SEQ ID NO: 03 to SEQ ID NO: 18) whose parent proteins are Gp63, A2, HSP70, and LiP2a, mapped using bioinformatics techniques. Alternatively, the present invention also relates to the chimeric protein defined by SEQ ID NO: 02, which does not contain a histidine tail. The mapped peptides and parent proteins are shown in Table 1. Table 1 - Novel peptides identified. Unpublished peptide identified Protein of origin SEQ ID Gp63 SEQ ID NO: 03 Gp63 SEQ ID NO: 04 Gp63 SEQ ID NO: 05 Gp63 SEQ ID NO: 06 Gp63 SEQ ID NO: 07 Gp63 SEQ ID NO: 08 Gp63 SEQ ID NO: 09 Gp63 SEQ ID NO: 10 Gp63 SEQ ID NO: 11 Gp63 SEQ ID NO: 12 Gp63 SEQ ID NO: 13 Gp63 SEQ ID NO: 14 Gp63 SEQ ID NO: 15 A2 SEQ ID NO: 16 HSP70 SEQ ID NO: 17 LiP2a SEQ ID NO: 18
[0017] In the present invention, the chimeric protein is composed of the peptide sequences shown in Table 1. Linkers are added between the peptides. Petition 870250034541, dated 04 / 30 / 2025, page 21 / 43 / 24 formed by glycine and serine, the chimeric protein also presents a histidine tail in the C-terminal portion. The histidine tail is added as a strategy for purifying the protein after its expression.
[0018] Thus, in the present invention, the chimeric protein can be defined by SEQ ID NO: 02, which does not have a histidine tail, and can be purified using methods such as size exclusion chromatography and cation exchange.
[0019] The chimeric QL protein is expressed by prokaryotic organisms, more specifically by the bacterium Escherichia coli. The following can be considered expression strains: Escherichia coli BL21 (DE3), Escherichia coli SHuffle T7 Express, or Escherichia coli Arctic Express (DE3). In these modes, the QL gene sequence can be optimized for prokaryotic expression using codon optimization tools, such as CodonOpt from IDT DNA. In eukaryotic expression modes, the QL gene sequence can also be optimized for heterologous expression. In prokaryotic expression modes, the gene sequence optimized for expression is defined by SEQ ID NO: 02.
[0020] In certain embodiments, the prokaryotic expression plasmid may be selected from a group comprising: pET21a, pET21b, pET28a, pET28b, pET30(ac), pET41(ac), among others; the pET28a expression vector being preferred.
[0021] To obtain QL, the pre-inoculum containing the transformed strain is subjected to heterologous expression at 37°C for 2 to 5 hours, after the addition of 0.2 to 0.5 mM IPTG. Then, the pellet and supernatant are separated by cold centrifugation. For protein exposure, the pellet is resuspended and lysed in a sonicator, centrifuged, and then the supernatant is purified by FPLC on an affinity column. Petition 870250034541, dated 04 / 30 / 2025, page 22 / 43 / 24
[0022] In alternative embodiments, the chimeric protein can be expressed without the histidine tail, and purified by methods such as size exclusion chromatography or cation exchange.
[0023] In the present invention, the chimeric protein exhibits immunogenic capacity, being able to induce the activation of B lymphocytes and consequent antibody production. Thus, the present invention relates to vaccine compositions comprising the recombinant chimeric protein defined by SEQ ID NO: 01.
[0024] To obtain the composition for use as a vaccine and / or diagnostic, the chimeric protein is expressed and purified. Then, the chimeric protein is treated to remove LPS. The LPS levels present in the protein after removal are preferably less than 1 EU / mL.
[0025] The present invention also relates to vaccine compositions comprising the chimeric protein, defined by SEQ ID NO:01, associated with pharmaceutically and pharmacologically accepted adjuvants and excipients.
[0026] Examples of adjuvants include aluminum salts (aluminum phosphate, aluminum hydroxide, aluminum and potassium sulfate), oil-in-water emulsions (MF59, AS03, AF03) and virosomes, but not exclusively.
[0027] Examples of pharmaceutically and pharmacologically accepted excipients include preservatives, colorants, flavor enhancers, sweeteners, thickeners, emulsifiers, stabilizers, or antioxidants. Examples include, but are not limited to, benzalkonium chloride, propylene glycol, lactose, and sorbitol.
[0028] Vaccine compositions can be administered via different routes, such as intramuscular, intranasal, oral, intradermal, intravenous, and subcutaneous. Petition 870250034541, dated 04 / 30 / 2025, page 23 / 43 / 24
[0029] The chimeric protein, presented within the scope of this invention, also comprises diagnostic kits for detecting the presence of anti-Leishmania antibodies, which are produced in cases of infection by the parasite. In the present invention, the diagnostic kit comprises: • Chimeric protein, defined by SEQ ID NO: 01 in powder, solution, compositions, or adhered to a solid support or carrier; • Secondary antibody or enzyme-conjugated protein or marker; • Selected enzyme detection reagent or marker.
[0030] In the present invention, the sample to be tested can be selected from a group comprising body fluids, such as whole blood, plasma and serum.
[0031] The solid support may be selected from a group comprising inert polymers such as carbon nanotubes, polystyrene, polypropylene, nylon, latex, or paper such as cellulose and nitrocellulose and other support materials. In the carrier embodiment, it may be selected from a group comprising gold particles, colored latex, or a molecule that can be subsequently identified by colorimetric labeling reagents.
[0032] The secondary antibody can be selected from a group comprising IgG, IgM, IgA, IgE and their respective parts or subclasses. In the detection protein mode, the protein can be selected from a group that exhibits the ability to bind with high affinity to the Fc portion of immunoglobulins, such as the proteins: Protein A and Protein G.
[0033] The detection enzyme may be selected from a group comprising alkaline phosphatase, peroxidase, β-galactosidase, urease, xanthine oxidase, glucose oxidase and penicillinase or other enzymes with reporter function; and the marker may be selected from a group comprising enzymes, radioisotopes, biotin, chromophores, fluorophores and chemiluminescents. Petition 870250034541, dated 04 / 30 / 2025, p. 24 / 43 / 24
[0034] In vitro and in vivo experiments, presented in this document, corroborate the immunogenic capacity of the developed chimeric protein. Thus, the present invention relates to the use of the chimeric protein defined by SEQ ID NO: 01 in the diagnosis and prophylaxis of Leishmaniasis, preferably in cats, dogs and humans. It also relates to the use of vaccine compositions comprising the protein defined by SEQ ID NO: 01 and pharmaceutically and pharmacologically acceptable adjuvants. It also relates to the use of SEQ ID NO: 02 for obtaining the chimeric protein QL from heterologous expression by a prokaryotic organism. Examples of embodiments of the invention
[0035] The present invention can be understood from, but is not limited to, the experiments described.
[0036] The tests performed to verify the immunological capacity of QL included statistical analyses that used the non-parametric ANOVA test - Kruskal-Wallis followed by Dunns. The significance level was defined as p<0.05 or p<0.01; using GraphPad Prism 6.0 software (San Diego, CA). Example 1: Obtaining the chimeric protein QL (SEQ ID NO: 01)
[0037] Initially, the proteins selected for epitope mapping were obtained from the NCBI public database. The proteins were used as input in the BepiPred 1.0 web server program for the identification of linear B-cell epitopes with a score greater than 1.3. In addition, linear CD4 and CD8 lymphocyte epitopes were identified using the NetMHCII and NetCTLpan programs. Subsequently, an in-house Perl script was optimized to select proteins that had antigenic regions in their sequences along at least 7 consecutive amino acids.
[0038] The chimeric protein with a novel sequence was constructed from the best selected epitopes, defined within the scope of this invention. Petition 870250034541, dated 04 / 30 / 2025, page 25 / 43 / 24, for sequences SEQ ID NO: 03 to SEQ ID NO: 18. Initial methionine was added to the protein sequence; a linker formed by glycine and serine was added between each epitope; and a histidine tail was added to the C-terminal portion for purification, the histidine tail being optional for implementing the invention. The chimeric protein QL, defined by SEQ ID NO: 01, can be obtained from expression in prokaryotic or eukaryotic organisms, with or without a histidine tail. Example 2: Heterologous expression and QL purification
[0039] In preferred embodiments, the nucleotide sequence defined by SEQ ID NO: 02 is inserted into the pET28a plasmid and expressed by Escherichia coli BL21. To obtain the transforming strain capable of expressing the protein, the pET28a plasmid is inserted into the expression organism by heat shock (Sambrook, J. and Russel, D.; Molecular Cloning: A Laboratory Manual).
[0040] For QL expression, a pre-inoculum containing 20 mL of LB medium supplemented with the plasmid selection antibiotic was prepared. The transforming strain was then kept overnight at 37 °C, rotating at 100 to 180 rpm. After the required time, the expression inoculum was prepared, comprising 20% v / v of the pre-inoculum in 1 liter of sterile LB medium with the addition of the same selection antibiotic. The inoculum was maintained at 37 °C, rotating at 180 rpm until reaching an OD600 of 0.4 to 0.6. Then, 0.2 to 0.5 mM of IPTG was added to the inoculum as an expression inducer. Expression was performed at 37 °C for a period of 2 to 5 hours. After the expression time was complete, the pellet and supernatant were separated by cold centrifugation.
[0041] The pellet was resuspended in a column-binding buffer solution composed of 20 mM dibasic sodium phosphate, 20 mM imidazole, and 500 mM sodium chloride. The contents were lysed using a sonicator (Sonics Vibra Cell™) on ice with a 60% amplitude, 30s pulse on and 30s pulse off for 5 minutes. The lysate was centrifuged again at cold temperatures. Petition 870250034541, dated 04 / 30 / 2025, page 26 / 43 / 24
[0042] The generated supernatant was purified using an Akta™ Start Purifier FPLC instrument (GE Healthcare / Cytiva), using a 5 mL His Trap FF affinity column, and eluted in an elution buffer solution containing 20 mM dibasic sodium phosphate, 500 mM sodium chloride, and 500 mM imidazole.
[0043] After purification, it was observed that the purified protein had high levels of lipopolysaccharides (LPS); which is an expected result, considering its expression by the prokaryotic system. Thus, the protein was subjected to the removal of the LPS present (Figure 1). For immunization, aliquots of purified QL containing a maximum of 10 ng of endotoxin per milligram of protein were used.
[0044] In certain modalities, techniques such as the use of an anion exchange column, in which endotoxins bind to the column and the protein of interest does not, as well as differential centrifugation with the addition of Triton X-114 (Aida, Y., Pabst, MJ; 1990. DOI: 10.1016 / 0022-1759(90)90029-u), can be used for LPS removal. Lipopolysaccharides can also be removed using purification kits such as Pierce™ High-Capacity Endotoxin Removal Resin (Thermo Fisher), EndoTrap® HD (LIONEX), and ToxinEraser™ Endotoxin Removal Kit (GenScript). Example 3: Recognition of the QL protein by serum from infected animals and patients.
[0045] The chimeric protein recognition test was performed using serum from dogs infected (C) and humans infected (D) with the Leishmania infantum species. Thus, it was verified whether the concatenation of peptides interferes with epitope recognition. In addition, recognition was tested for QL at concentrations of 0.1; 0.5 and 1.0 pg / mL (Figure 4).
[0046] The plates were sensitized with 0.1 pg / mL, 0.5 pg / mL, or 1.0 pg / mL of QL protein and incubated for 12 hours. After this period, the plates were Petition 870250034541, dated 04 / 30 / 2025, page 27 / 43 17 / 24 plates were washed with PBS-Tween buffer to remove excess unadsorbed protein and blocked with 3% PBS-Tween BSA buffer for 1 hour. The buffer was discarded, and 100 pL of serum diluted 1 / 100 from dogs or humans was added for 2 hours. After washing the plates, 100 pL of peroxidase-labeled secondary antibody was added and incubated for 1 hour. After washing the plates, TMB (tetramethylbenzene) substrate was added for 30 minutes, which reacts by changing color. Finally, 2N sulfuric acid was added to stop the reaction. The QL protein was recognized by antibodies present in the serum of dogs and humans infected with the parasite L. infantum. Most importantly, it was observed that the use of the QL protein was able to detect parasites in the serum of infected dogs and humans; and to differentiate the serum of uninfected dogs and humans. This validates the diagnostic capacity of the QL protein. Example 4: In vivo evaluation of QL antigenicity
[0047] To evaluate the immunogenic capacity of QL, expressed in prokaryotes, the purified protein with LPS less than 1 EU / mL was used. Immunogenicity was evaluated from single-dose immunization (Immunogenicity Test I) or from three doses (Immunogenicity Test II).
[0048] In the experimental design, 8 animals received the control treatment, while 8 animals were immunized with the vaccine composition, for each evaluation time.
[0049] The control dose used consists of 50 pL of sterile 1x PBS. The dose of the vaccine composition administered comprised 25 to 10 µg of QL protein diluted in water.
[0050] Vaccine compositions can be administered orally, intradermally, intramuscularly, or intravenously. For effectiveness testing, the intravenous route is commonly used. • Immunogenicity test I: Petition 870250034541, dated 04 / 30 / 2025, page 28 / 43 / 24
[0051] To evaluate the immunogenicity of QL, administered in a single dose, 25 μg of purified QL diluted in water to a final volume of 50 pL was used. 16 BALB / c mice were immunized; 8 were the control group, and 8 were the test group. Sera were collected 4 weeks after immunization. The collected sera were subjected to indirect ELISA to verify the protein's ability to activate B lymphocytes and, consequently, the production of specific antibodies against parasites of the genus Leishmania. Thus, indirect ELISA was used to verify if immunization using the QL protein was able to induce the production of antibodies that specifically recognize the chimeric protein (A), and if they are able to recognize soluble antigens of the parasite (B).
[0052] The plates were sensitized with 1 pg / mL of QL protein or 5 pg / mL of soluble protein and incubated for 12 hours. After this period, the plates were washed with PBS-Tween buffer to remove excess unadsorbed protein and blocked with 3% PBS-Tween BSA buffer for 1 hour. The buffer was discarded, and 100 μL of serum diluted 1 / 100 from mice immunized with PBS or QL protein was added for 2 hours. After washing the plates, 100 pL of peroxidase-labeled secondary antibody was added and incubated for 1 hour. After washing the plates, TMB substrate was added for 30 minutes, which reacts by changing color. Finally, 2N sulfuric acid was added to stop the reaction.
[0053] It was observed that immunization with a single 25pg dose of QL protein was not sufficient to induce a large production of antibodies. Therefore, a new test was performed to evaluate the use of the protein in a larger number of doses. • Immunogenicity test II:
[0054] To evaluate the immunogenicity of QL, administered in three doses, three doses containing 10 pg / dose were used, with a 7-day interval between doses. Five BALB / c mice were immunized with the tested protein and the Petition 870250034541, dated 04 / 30 / 2025, page 29 / 43 / 24 serum samples were collected 7 days after each dose. After 4 weeks of immunization, the 5 animals were euthanized (4wpi).
[0055] The collected sera were subjected to indirect ELISA to verify the protein's ability to activate B lymphocytes, and consequently, the production of specific antibodies against parasites of the genus Leishmania (Figure 3).
[0056] The ability to induce B cell activation was verified by indirect ELISA. Plates were sensitized with 1 pg / mL of QL protein and incubated for 12 hours. After this period, the plates were washed with PBS-Tween buffer to remove excess unadsorbed protein and blocked with 3% PBS-Tween BSA buffer for 1 hour. The buffer was discarded, and 100 pL of serum diluted 1 / 100 from mice immunized with QL protein was added for 2 hours. After washing the plates, 100 pL of peroxidase-labeled secondary antibody was added and incubated for 1 hour. After washing the plates, TMB substrate was added for 30 minutes, which reacts by changing color. Finally, 2N sulfuric acid was added to stop the reaction.
[0057] Based on the quantification of total IgG by indirect ELISA, it was observed that immunization with a greater number of doses, and a decrease in the amount of QL protein per dose, was able to induce a strong dose-dependent response, activating B cells and consequently inducing the production of antibodies that recognize the protein. Example 4: Immunization challenge
[0058] Four weeks after immunization, animals immunized with PBS and those immunized with the chimeric protein were challenged intravenously with 3x10⁶ of wild-type L. infantum PP75 parasites. After the challenge, the following animals were euthanized: 8 animals four weeks after immunization (4wpc), 8 animals eight weeks after immunization (8wpc), and 8 animals twelve weeks after immunization (12wpc). Petition 870250034541, dated 04 / 30 / 2025, page 30 / 43 / 24 Example 5: Evaluation of IgG production after the challenge.
[0059] Serum from animals sacrificed at 4wpi, 4wpc, 8wpc, and 12 wpc times was used to evaluate the levels of antibodies produced using the indirect ELISA technique (Figure 8). Thus, the production of total IgG (H1), IgG1 (H2), and IgG2 (H3) was evaluated.
[0060] The ability to induce B cell activation was verified by indirect ELISA. Plates were sensitized with 5 pg / mL of soluble L. infantum proteins and incubated for 12 hours. After this period, the plates were washed with PBS-Tween buffer to remove excess unadsorbed protein and blocked with 3% PBS-Tween BSA buffer for 1 hour. The buffer was discarded, and 100 pL of serum diluted 1 / 100 from each mouse immunized with QL protein or PBS and challenged was added for 2 hours. After washing the plates, 100 pL of peroxidase-labeled anti-mouse secondary antibody was added and incubated for 1 hour. After washing the plates, TMB substrate was added for 30 minutes, which reacts by changing color. Finally, 2N sulfuric acid was added to stop the reaction.
[0061] The results observed in the quantification of total IgG (H1), IgG1 (H2) and IgG2 (H3) confirm the ability of QL to induce strong B cell activation, before and after challenge, regardless of the time elapsed since the challenge, when compared to animals immunized with the PBS control. This result demonstrates the robustness of the immune response induced by the protein, even after infection with the parasite. Example 6: Test for activating memory T lymphocytes through the production of soluble factors (cytokines)
[0062] Splenocytes from euthanized animals (obtained at 4wpi, 4wpc, 8 wpc, and 12 wpc) were stimulated with soluble parasite proteins obtained through sonication, and the culture supernatant was collected for evaluation of Petition 870250034541, dated 04 / 30 / 2025, page 31 / 43 / 24 levels of cytokines produced, through the Luminex technique (MultiplexInvitrogen) using the ProcartaPlex Mo Th1 / Th2 / Th9 / Th17 / Th22 / Treg 17plex kit.
[0063] Thus, the production of pro-inflammatory cytokines (Figure 5), anti-inflammatory cytokines (Figure 6), and Th17 cytokines (Figure 7) was evaluated. From the generated data, a statistical analysis (p<0.05) was performed between the Luminex results of control animals versus immunized animals. The statistical analysis showed a significant increase in pro-inflammatory, anti-inflammatory, and Th17 cytokines at different times after the challenge. • Assessment of the production of pro-inflammatory cytokines
[0064] In the context of immunization, the evaluation of pro-inflammatory cytokines allows assessing the protein's ability to induce the production of specific long-lasting T lymphocytes, as well as the activation of these cells, through the production of cytokines.
[0065] No significant differences were identified between the pro-inflammatory cytokines produced by control and immunized and unchallenged animals (4wpi) and also between control and immunized animals euthanized 4 weeks after challenge (4wpc).
[0066] The cytokines IL-Iβ (E1) and GM-CSF (E7) showed a significant increase after 8 weeks of challenge (8wpc) and after 12 weeks of challenge. The increase in these cytokines by immunized animals indicates induction of cell proliferation and differentiation by immunization with the protein in response to infection.
[0067] The cytokines IL-6 (E3), IL-12p70 (E6) and TNF-α (E8) showed a significant increase in production, comparing the immunized group to the control group, only after 8 weeks of challenge (8wpc); which indicates that cells from animals immunized with QL are inducing inflammation, cell proliferation, NK cell activation, antimicrobial response, and regulating this induced inflammation. Petition 870250034541, dated 04 / 30 / 2025, page 32 / 43 / 24
[0068] The cytokine IL-23 (E4) showed a significant increase in its production, compared to the control group, only after 12 weeks of challenge (12wpc). This indicates that cells from animals immunized with QL are mediating inflammation, regulating tissue damage.
[0069] On the other hand, no significant increase in the cytokines IL-2 (E2) and IFN-γ (E5) was observed in the immunized groups at any time evaluated, despite the graph showing a slight increase in the production of these cytokines by the immunized group. • Evaluation of the production of anti-inflammatory cytokines
[0070] In the context of immunization, the evaluation of pro-inflammatory cytokines shows that there was greater production of the pro-inflammatory cytokines IL-1e (E1), IL-6 (E3), IL-23 (E4), IL-12p70 (E6), GM-CSF (E7) and TNF-α (E8) in the group immunized with the chimeric protein. Conversely, the evaluation of anti-inflammatory cytokines shows that immunization with the QL protein induced greater production of the cytokines IL-10 (F1), IL-5 (F2), IL-9 (F3), IL-13 (F4) and IL-27 (F5) compared to the control group (p=0.01). These cytokines are involved in the regulation of inflammation and tissue damage.
[0071] These findings allow us to conclude that immunization with the QL protein is capable of inducing long-lasting T lymphocyte activation with a balanced profile. Therefore, it has the potential to help the host avoid developing the disease. • Evaluation of Th17 cytokine production
[0072] In the context of immunization challenge, the evaluation of IL-22 cytokine produced by Th17 profile cells (Figure 7) allows us to assess that animals immunized with the chimera showed higher IL-22 production (G1) compared to the control group (p<0.05) 8 and 12 weeks after the challenge. This Petition 870250034541, dated 04 / 30 / 2025, page 33 / 43 / 24: This cytokine is involved in tissue damage repair, making the induction of this cytokine by cells of mice immunized with the QL protein and infected extremely important at these times. The production of the cytokine IL-17A, produced by Th17 profile cells, allows us to assess that animals immunized with the chimera showed higher IL-17A production compared to the control group (p=0.01) 12 weeks after the challenge. This cytokine is involved in the induction of chemokine production and recruitment of innate immune cells to assist in parasite control, making the induction of this cytokine by cells of mice immunized with the QL protein and infected extremely important at these times. Example 7: Evaluation of parasite load
[0073] The parasite load assessment was performed using spleen and liver samples from animals euthanized after the challenge, i.e., 4wpc, 8 wpc and 12 wpc (Figure 9).
[0074] For evaluation of parasite load, spleen and liver were collected from animals challenged with a wild strain of Leishmania infantum to verify the parasite load, using the serial dilution technique. A lower number of parasites was observed in the spleen (I2) and liver (I2) of animals in the group immunized with the chimeric protein at time 12wpc. Conclusion
[0075] The present invention discloses a chimeric protein, defined by SEQ ID NO:01, capable of inducing an anti-Leishmania immune response in a model organism. The disclosed protein can be expressed in prokaryotic and eukaryotic organisms. Vaccine compositions containing the purified protein expressed in a prokaryotic organism demonstrated humoral and cellular protection in individuals vaccinated in 3 doses, with a 7-week interval between doses. The present invention also discloses the ability of the disclosed protein Petition 870250034541, dated 04 / 30 / 2025, page 34 / 43 / 24, regarding the identification of the parasite causing leishmaniasis through serological diagnosis, such as ELISA. Thus, the present invention discloses an immunogenic chimeric protein, vaccine compositions containing it, and diagnostic kits containing this protein. Petition 870250034541, dated 04 / 30 / 2025, pages 35 / 43
Claims
1 / 2 CLAIMS 1. Chimeric protein, characterized by being defined by SEQ ID NO: 01 or, alternatively, by being defined by SEQ ID NO: 02 2. Chimeric protein, according to claim 1, characterized by comprising the peptide sequences defined by SEQ ID NO: 03, SEQ ID NO: 04, SEQ ID NO: 05, SEQ ID NO: 06, SEQ ID NO: 07, SEQ ID NO: 08, SEQ ID NO: 09, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO:
18.
3. Vaccine compositions, characterized by comprising the chimeric protein SEQ ID NO: 01, or SEQ ID NO: 02, described in any of the preceding claims, associated with pharmaceutically and pharmacologically accepted excipients, such as preservatives, colorants, flavorings, sweeteners, thickeners, emulsifiers, stabilizers or antioxidants.
4. Vaccine compositions according to claim 3, characterized by comprising the chimeric protein SEQ ID NO: 01, or SEQ ID NO: 02, associated with adjuvants such as aluminum salts, such as aluminum phosphate, aluminum hydroxide, aluminum and potassium sulfate; oil-in-water emulsions such as MF59, AS03, AF03 and virosomes, not exclusively.
5. Vaccine compositions, according to claims 3 and 4, characterized by the route of administration being selected from a group comprising: intramuscular, intranasal, oral, intradermal, intravenous and subcutaneous routes.
6. Diagnostic kit, which uses the chimeric protein defined by any of the preceding claims, characterized by comprising: • Chimeric protein, defined by SEQ ID NO: 01 in powder, in solution, in compositions, or adhered to a solid support or carrier; • Secondary antibody or protein conjugated to an enzyme or marker; Petition 870250034541, dated 04 / 30 / 2025, p. 36 / 43 2 / 2 • Selected enzyme or marker detection reagent.
7. Diagnostic kit, according to claim 6, characterized in that the sample evaluated is selected from a group comprising: body fluids, such as whole blood, plasma and serum.
8. Diagnostic kit, according to claim 6, characterized in that the solid support is selected from a group comprising inert polymers such as carbon nanotubes, polystyrene, polypropylene, nylon, latex, or paper such as cellulose and nitrocellulose and other support materials, and in the carrier embodiment it may be selected from a group comprising gold particles, colored latex, or a molecule that can be subsequently identified by colorimetric labeling reagents.
9. Diagnostic kit, according to claim 6, characterized by the secondary antibody being selected from a group comprising: IgG, IgM, IgA, IgE and their respective parts or subclasses. In the detection protein embodiment, the protein may be selected from a group that exhibits the ability to bind with high affinity to the Fc portion of immunoglobulins, such as Protein A and Protein G.
10. Diagnostic kit, according to claim 6, characterized in that the detection enzyme can be selected from a group comprising alkaline phosphatase, peroxidase, β-galactosidase, urease, xanthine oxidase, glucose oxidase and penicillinase or other enzymes with reporter function; and the marker can be selected from a group comprising enzymes, radioisotopes, biotin, chromophores, fluorophores and chemiluminescents.
11. Use of the chimeric protein defined in claim 1, characterized by being for the production of a diagnostic and prophylactic kit for Leishmaniasis, preferably in cats, dogs and humans.
12. Use of the chimeric protein defined in claim 1, characterized by being for the production of vaccines for the prevention of leishmaniasis. Petition 870250034541, dated 04 / 30 / 2025, pp. 37 / 43
